

## Special Issue

# Streptococcal Vaccines: Current Status and Future Directions

### Message from the Guest Editor

Streptococcal infections are among the most common bacterial infections. Among Streptococcal species, three are of significant concern: (a) Group B Streptococcus (GBS), causing serious infections like pneumonia, sepsis, and meningitis; (b) *Streptococcus pneumoniae*, causing a common community-acquired pneumonia, particularly in young children and the elderly; and (c) Group A Streptococcus (GAS), causing strep throat, skin and bloodstream infections, and deadly rheumatic heart diseases. Vaccines against *S. pneumoniae* are available (e.g., Prevenar 13, Pneumovax 23); however, they do not offer universal protection, while vaccines against other *streptococci* are in development. Given the global spread, growing antibiotic resistance, and high mortality rate related to systemic infections and autoimmune postinfection complications, the need for the development of vaccines against these bacteria is of high priority.

- Vaccine development against Group A or B Streptococcus;
- Vaccines targeting other *Streptococcal* species;
- Adjuvants in streptococcal vaccines;
- Animal models for streptococcal vaccines;
- Clinical trials on the Streptococcal vaccines.

---

### Guest Editor

Dr. Mariusz Skwarczynski

School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia

---

### Deadline for manuscript submissions

31 July 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/249220](https://mdpi.com/si/249220)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).